AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19004402 — intervention group
Group type: COMPARATOR
Intervention: Dry toilet tissue for 28 days
Number of subjects: 180
Study 19004402 — intervention group
Group type: EXPERIMENTAL
Intervention: Feminine hygiene wet wipes for postmenopausal women
Number of subjects: 180
Study 19004402 — intervention group
Group type: EXPERIMENTAL
Intervention: Feminine hygiene wet wipes for premenopausal women
Number of subjects: 180
Study 15671131 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysubstance misuse (Ecstasy, amphetamine, cocaine, alcohol, cannabis)
Number of subjects: 50
Study 15671131 — intervention group
Group type: COMPARATOR
Intervention: Alcohol/cannabis misuse
Number of subjects: 50
Study 15566660 — intervention group
Group type: EXPERIMENTAL
Intervention: Sheng Ban Recipe (SBR) plus common treatment
Number of subjects: 103
Study 15566660 — intervention group
Group type: COMPARATOR
Intervention: Common treatment alone
Number of subjects: 103
Study 11414671 — intervention group
Group type: EXPERIMENTAL
Intervention: COSMED K4 b2 portable metabolic measurement system
Number of subjects: 0
Study 9326685 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefabricated sheath (110 degrees curved tip)
Number of subjects: 5
Study 9326685 — intervention group
Group type: COMPARATOR
Intervention: Specially curved sheath (two curves)
Number of subjects: 5
Study 7951847 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (OPZ) 20 mg/day
Number of subjects: 44
Study 7951847 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (OPZ) 20 mg/day plus Pirenzepine (PZP) 100 mg/day
Number of subjects: 44
Study 3114506 — intervention group
Group type: EXPERIMENTAL
Intervention: Administration sets replaced at 72-hour intervals
Number of subjects: 487
Study 3114506 — intervention group
Group type: COMPARATOR
Intervention: Administration sets replaced at 48-hour intervals
Number of subjects: 487
Study 29253630 — intervention group
Group type: EXPERIMENTAL
Intervention: Presurgery physiotherapy
Number of subjects: 197
Study 29253630 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list group (control)
Number of subjects: 197
Study 26537478 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐T4 administered with breakfast
Number of subjects: 61
Study 26537478 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐T4 taken 10 min before breakfast
Number of subjects: 61
Study 26537478 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐T4 administered at 0-10 min intervals before breakfast
Number of subjects: 61
Study 26537478 — intervention group
Group type: COMPARATOR
Intervention: L‐T4 taken 30 min before breakfast
Number of subjects: 61
Study 24664615 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes self-management intervention
Number of subjects: 252
Study 24664615 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 252
Study 23393185 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec (IDeg) Forced-Flex once daily
Number of subjects: 0
Study 23393185 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec (IDeg) once daily
Number of subjects: 0
Study 23393185 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine (IGlar) once daily
Number of subjects: 0
Study 23393185 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec (IDeg) Forced-Flex
Number of subjects: 0
Study 23393185 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec (IDeg)
Number of subjects: 0
Study 23393185 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec (IDeg) Free-Flex
Number of subjects: 0
Study 23393185 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine (IGlar)
Number of subjects: 0
Study 23393185 — intervention group
Group type: COMPARATOR
Intervention: Insulin degludec (IDeg) and Insulin glargine (IGlar)
Number of subjects: 0
Study 21122389 — intervention group
Group type: EXPERIMENTAL
Intervention: slow-release 5-fluorouracil implantation
Number of subjects: 85
Study 21122389 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 85
Study 18414107 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost/timolol fixed combination (FC)
Number of subjects: 1061
Study 18414107 — intervention group
Group type: COMPARATOR
Intervention: Bimatoprost (BIM)
Number of subjects: 1061
Study 18414107 — intervention group
Group type: COMPARATOR
Intervention: Timolol (TIM)
Number of subjects: 1061
Study 16586071 — intervention group
Group type: COMPARATOR
Intervention: Natural interferon-alpha alone
Number of subjects: 71
Study 16586071 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural interferon-alpha plus cimetidine
Number of subjects: 71
Study 12730285 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent siblings of childhood cancer survivors
Number of subjects: 78
Study 10781460 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 1 microg/kg
Number of subjects: 60
Study 10781460 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 3 mg
Number of subjects: 60
Study 10781460 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of clonidine 1 microg/kg and morphine 3 mg
Number of subjects: 60
Study 10781460 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.25%
Number of subjects: 60
Study 8624003 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium initial dose of 144 micrograms.kg‐1 in cirrhotic patients
Number of subjects: 50
Study 8624003 — intervention group
Group type: COMPARATOR
Intervention: Rocuronium initial dose of 60 micrograms.kg‐1 in control subjects
Number of subjects: 50
Study 8624003 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance doses of 75, 150, or 225 micrograms.kg‐1 administered at 25% recovery of twitch height in cirrhotic patients
Number of subjects: 50
Study 8624003 — intervention group
Group type: COMPARATOR
Intervention: Maintenance doses of 75, 150, or 225 micrograms.kg‐1 administered at 25% recovery of twitch height in control subjects
Number of subjects: 50
Study 8624003 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium in cirrhotic patients receiving five maintenance doses or more
Number of subjects: 50
Study 8624003 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium in cirrhotic patients
Number of subjects: 50
Study 8624003 — intervention group
Group type: COMPARATOR
Intervention: Rocuronium in control subjects
Number of subjects: 50
Study 1410233 — intervention group
Group type: EXPERIMENTAL
Intervention: Various biomedical, behavioral, and environmental interventions
Number of subjects: 0
Study 1410233 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life measures
Number of subjects: 0
Study 1410233 — intervention group
Group type: EXPERIMENTAL
Intervention: Common measures of quality of life
Number of subjects: 0
Study 1410233 — intervention group
Group type: EXPERIMENTAL
Intervention: Preliminary observations from FICSIT
Number of subjects: 0
Study 3993154 — intervention group
Group type: EXPERIMENTAL
Intervention: L-penbutolol
Number of subjects: 12
Study 3993154 — intervention group
Group type: EXPERIMENTAL
Intervention: D-penbutolol
Number of subjects: 12
Study 3993154 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29995952 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate-rich beetroot juice supplementation
Number of subjects: 12
Study 29995952 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 12
Study 26794682 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasotraline 8 mg
Number of subjects: 48
Study 26794682 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasotraline 16 mg
Number of subjects: 48
Study 26794682 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasotraline 36 mg
Number of subjects: 48
Study 26794682 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 40 mg
Number of subjects: 48
Study 26794682 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 80 mg
Number of subjects: 48
Study 26794682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 24088915 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP=5 cmH2O (Group A)
Number of subjects: 136
Study 24088915 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP=8 cmH2O (Group B)
Number of subjects: 136
Study 24088915 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP=10 cmH2O (Group C)
Number of subjects: 136
Study 22892804 — intervention group
Group type: EXPERIMENTAL
Intervention: Semont maneuver
Number of subjects: 128
Study 22892804 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 128
Study 20937127 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline 100 mg or 200 mg daily
Number of subjects: 20
Study 18538109 — intervention group
Group type: EXPERIMENTAL
Intervention: CR002 (0.3, 1, 3, 10, 30 mg/kg)
Number of subjects: 40
Study 18538109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 18538109 — intervention group
Group type: EXPERIMENTAL
Intervention: CR002
Number of subjects: 40
Study 16203881 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-stem cementless calcar-replacement prosthesis
Number of subjects: 58
Study 16203881 — intervention group
Group type: COMPARATOR
Intervention: Proximal femoral nail
Number of subjects: 58
Study 12701733 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipsilateral 45 dB HL 250 Hz narrow-band noise (NBN)
Number of subjects: 16
Study 12701733 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralateral 45 dB HL 250 Hz narrow-band noise (NBN)
Number of subjects: 16
Study 12701733 — intervention group
Group type: COMPARATOR
Intervention: 90 dB HL 2 kHz pure tone
Number of subjects: 16
Study 10337860 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and alcohol (0.4 g/kg body weight)
Number of subjects: 23
Study 10337860 — intervention group
Group type: COMPARATOR
Intervention: Exercise alone (30 minutes at 40% VO2max)
Number of subjects: 23
Study 10337860 — intervention group
Group type: COMPARATOR
Intervention: Resting state
Number of subjects: 23
Study 10337860 — intervention group
Group type: COMPARATOR
Intervention: Alcohol alone
Number of subjects: 23
Study 10337860 — intervention group
Group type: COMPARATOR
Intervention: Alcohol intake
Number of subjects: 23
Study 10142127 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumer case managers
Number of subjects: 0
Study 10142127 — intervention group
Group type: COMPARATOR
Intervention: Nonconsumer case managers
Number of subjects: 0
Study 2143593 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (360 micrograms total, 60 micrograms into each nostril, repeated twice at 15 min intervals)
Number of subjects: 20
Study 2143593 — intervention group
Group type: COMPARATOR
Intervention: Control (age‐sex matched subjects)
Number of subjects: 20
Study 7299611 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple instillation of aqueous phenylephrine 2.5% and tropicamide 1.0%
Number of subjects: 52
Study 7299611 — intervention group
Group type: EXPERIMENTAL
Intervention: Single instillation of phenylephrine 2.5%, tropicamide 0.5%, and cyclogyl 0.5%
Number of subjects: 52
Study 7299611 — intervention group
Group type: COMPARATOR
Intervention: Balanced salt solution (placebo)
Number of subjects: 52
Study 31422879 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexrazoxane-Anthracyclines association
Number of subjects: 20
Study 31422879 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 20
Study 30167830 — intervention group
Group type: EXPERIMENTAL
Intervention: Indwelling catheter (French 16)
Number of subjects: 75
Study 30167830 — intervention group
Group type: COMPARATOR
Intervention: No catheter
Number of subjects: 75
Study 26260705 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ghrelin at 1 μg/kg or 2 μg/kg, twice daily for 3 weeks
Number of subjects: 18
Study 26019878 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% reduced basal insulin dose with reduced prandial bolus insulin and LGI carbohydrate feeding
Number of subjects: 10
Study 26019878 — intervention group
Group type: COMPARATOR
Intervention: 100% basal insulin dose
Number of subjects: 10
Study 23140985 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetics (A)
Number of subjects: 45
Study 23140985 — intervention group
Group type: COMPARATOR
Intervention: Local anesthetics and lavage (AL)
Number of subjects: 45
Study 23140985 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and AL)
Number of subjects: 45
Study 21228629 — intervention group
Group type: COMPARATOR
Intervention: RIX4414 vaccine stored at 2 °C‐8 °C (Group RIX4414_control, n = 171)
Number of subjects: 218
Study 21228629 — intervention group
Group type: EXPERIMENTAL
Intervention: RIX4414 vaccine stored at 37 °C for 7 days (Group RIX4414_37 °C, n = 47)
Number of subjects: 218
Study 21228629 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo group (n = 25)
Number of subjects: 218
Study 19480560 — intervention group
Group type: EXPERIMENTAL
Intervention: UK-453,061 (non-nucleoside reverse transcriptase inhibitor)
Number of subjects: 0
Study 17541023 — intervention group
Group type: EXPERIMENTAL
Intervention: 17beta‐estradiol (0.05 mg/d)
Number of subjects: 100
Study 17541023 — intervention group
Group type: EXPERIMENTAL
Intervention: 17beta‐estradiol (0.05 mg/d) + norethindrone acetate (NETA, 0.14 mg/d)
Number of subjects: 100
Study 17541023 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 17541023 — intervention group
Group type: EXPERIMENTAL
Intervention: GTN-D response
Number of subjects: 100
Study 14720083 — intervention group
Group type: EXPERIMENTAL
Intervention: Data Safety Monitoring Boards (DSMBs)
Number of subjects: 0
Study 14720083 — intervention group
Group type: EXPERIMENTAL
Intervention: Interim analyses
Number of subjects: 0
Study 14720083 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial sponsor responsibility
Number of subjects: 0
Study 11431238 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS (1 Hz, 110% motor threshold)
Number of subjects: 18
Study 11431238 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS (1 Hz, 20% motor threshold)
Number of subjects: 18
Study 11930385 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 grams of psyllium hydrophilic mucilloid per day
Number of subjects: 46
Study 11930385 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 46
Study 8852740 — intervention group
Group type: EXPERIMENTAL
Intervention: Maltose (0.05g maltose/kg body-weight/hour for 5 days)
Number of subjects: 0
Study 8852740 — intervention group
Group type: COMPARATOR
Intervention: Glucose (isocaloric completed nutritional solution)
Number of subjects: 0
Study 1519576 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 800 mg evening dose
Number of subjects: 186
Study 1519576 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg evening dose
Number of subjects: 186
Study 1519576 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg evening dose
Number of subjects: 186
Study 6826108 — intervention group
Group type: EXPERIMENTAL
Intervention: Bombesin (10 ng/kg/min)
Number of subjects: 41
Study 6826108 — intervention group
Group type: COMPARATOR
Intervention: Gastrin response to meal
Number of subjects: 41
Study 6826108 — intervention group
Group type: EXPERIMENTAL
Intervention: Bombesin
Number of subjects: 41
Study 31475415 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg/day trans‐resveratrol
Number of subjects: 71
Study 31475415 — intervention group
Group type: COMPARATOR
Intervention: placebo (methyl cellulose)
Number of subjects: 71
Study 29318278 — intervention group
Group type: EXPERIMENTAL
Intervention: Idalopirdine 60 mg/d
Number of subjects: 2525
Study 29318278 — intervention group
Group type: EXPERIMENTAL
Intervention: Idalopirdine 30 mg/d
Number of subjects: 2525
Study 29318278 — intervention group
Group type: EXPERIMENTAL
Intervention: Idalopirdine 10 mg/d
Number of subjects: 2525
Study 29318278 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2525
Study 26924562 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesteatoma group
Number of subjects: 549
Study 26924562 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 549
Study 24794447 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil 1μg/kg
Number of subjects: 40
Study 24794447 — intervention group
Group type: COMPARATOR
Intervention: Control (no intrathecal sufentanil)
Number of subjects: 40
Study 22758921 — intervention group
Group type: EXPERIMENTAL
Intervention: Translating Research into Practice (TRIP) intervention
Number of subjects: 0
Study 22758921 — intervention group
Group type: COMPARATOR
Intervention: Control sites
Number of subjects: 0
Study 20921983 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic mixture (Lactobacillus rhamnosus GR‐1 and Bifidobacterium adolescentis isolate in yogurt)
Number of subjects: 36
Study 20921983 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 36
Study 18925530 — intervention group
Group type: COMPARATOR
Intervention: Urinary PC‐1 excretion in IgA nephropathy group
Number of subjects: 178
Study 18925530 — intervention group
Group type: COMPARATOR
Intervention: Urinary NAGA excretion in membranous nephropathy group
Number of subjects: 178
Study 18925530 — intervention group
Group type: COMPARATOR
Intervention: APN excretion in diabetic nephropathy group
Number of subjects: 178
Study 18925530 — intervention group
Group type: COMPARATOR
Intervention: Urinary APN activity in type 1 and type 2 diabetic patients with microalbuminuria
Number of subjects: 178
Study 18925530 — intervention group
Group type: COMPARATOR
Intervention: Urinary NAGA and DPP IV activities in type 2 diabetics with microalbuminuria
Number of subjects: 178
Study 18925530 — intervention group
Group type: COMPARATOR
Intervention: Serum PC‐1 and APN activities in membranous nephropathy group
Number of subjects: 178
Study 18925530 — intervention group
Group type: COMPARATOR
Intervention: Serum PC‐1 and DPP IV activities in IgA nephropathy patients
Number of subjects: 178
Study 18925530 — intervention group
Group type: COMPARATOR
Intervention: Serum DPP IV and APN activity in type 2 diabetics with microalbuminuria
Number of subjects: 178
Study 15741753 — intervention group
Group type: EXPERIMENTAL
Intervention: Satraplatin 100 mg/m² for 5 days plus prednisone 10 mg orally BID
Number of subjects: 50
Study 15741753 — intervention group
Group type: COMPARATOR
Intervention: Prednisone alone
Number of subjects: 50
Study 12393614 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone (10 mg/m² per day x 5) and Etoposide (100 mg/m² per day x 5)
Number of subjects: 328
Study 12393614 — intervention group
Group type: COMPARATOR
Intervention: Cytarabine (200 mg/m² per day x 7) and Daunorubicin (45 mg/m² per day x 3)
Number of subjects: 328
Study 10355069 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 1000
Study 10355069 — intervention group
Group type: EXPERIMENTAL
Intervention: Cordichin (fixed combination of chinidin and verapamil)
Number of subjects: 1000
Study 10355069 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic antiarrhythmic drug administration (Sotalol or Cordichin)
Number of subjects: 1000
Study 10355069 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiarrhythmic medication (Sotalol or Cordichin)
Number of subjects: 1000
Study 10355069 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study 7860762 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic hyponatremia patients
Number of subjects: 12
Study 7860762 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic hyponatremia patients (4 patients studied 8-14 weeks later)
Number of subjects: 12
Study 7860762 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 12
Study 1789379 — intervention group
Group type: EXPERIMENTAL
Intervention: TRH (500 micrograms)
Number of subjects: 8
Study 1789379 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.8 g/kg)
Number of subjects: 8
Study 1789379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 1789379 — intervention group
Group type: EXPERIMENTAL
Intervention: TRH (500 micrograms) with ethanol
Number of subjects: 8
Study 31422103 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic health record alerts and communication coaching for hospitalists
Number of subjects: 14
Study 31422103 — intervention group
Group type: COMPARATOR
Intervention: Control group (no alerts or coaching)
Number of subjects: 14
Study 30079432 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (up to 45 mg/day)
Number of subjects: 24
Study 30079432 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 30079432 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 24
Study 25622713 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenous intraoral block graft
Number of subjects: 10
Study 25622713 — intervention group
Group type: COMPARATOR
Intervention: Autogenous particulate graft
Number of subjects: 10
Study 24886444 — intervention group
Group type: EXPERIMENTAL
Intervention: ART sealant
Number of subjects: 280
Study 24886444 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride-releasing resin sealant
Number of subjects: 280
Study 24886444 — intervention group
Group type: COMPARATOR
Intervention: Topical fluoride application
Number of subjects: 280
Study 22160347 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent training intervention based on the TEACCH model
Number of subjects: 20
Study 22160347 — intervention group
Group type: COMPARATOR
Intervention: Waitlist group (control)
Number of subjects: 20
Study 20299993 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral nerve block (group B)
Number of subjects: 60
Study 20299993 — intervention group
Group type: COMPARATOR
Intervention: Intravenous opioids (group O)
Number of subjects: 60
Study 17296819 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ferric gluconate (FG) 125 mg weekly for 8 weeks
Number of subjects: 187
Study 17296819 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ferrous sulfate 325 mg three times daily for 8 weeks
Number of subjects: 187
Study 17296819 — intervention group
Group type: COMPARATOR
Intervention: No iron
Number of subjects: 187
Study 16100476 — intervention group
Group type: EXPERIMENTAL
Intervention: Radionuclide angiography and SPECT using Tc‐99m MIBI
Number of subjects: 36
Study 12269969 — intervention group
Group type: EXPERIMENTAL
Intervention: Alicaforsen (ISIS 2302) 300 mg, infused intravenously three times a week for 4 weeks
Number of subjects: 22